How would you approach a patient with Stage III EGFR+ NSCLC who develops oligometastatic disease while on consolidation durvalumab?

Topics: Thoracic Malignancies • Medical Oncology • NCI-CCC Tumor Board Question • Ohio State University

Given the potential high risk of developing pneumonitis with TKI post checkpoint inhibitor, do you avoid TKIs and try a different regimen (ex carbo/paclitaxel/bev +/- atezo)?

Answer from: Medical Oncologist at Community Practice

This is a difficult situation, I have typically tried local therapies like SBRT initially and then switching to osimertinib with close followup and return precautions

Related Questions